Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7291 to 7305 of 7675 results

  1. Erdafitinib for previously treated FGFR-positive advanced solid tumours in people aged 6 and over [ID4058]

    In development [GID-TA10937] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. BPMpathway for rehabilitation support in joint replacement surgery (MIB319)

    MIB319 BPMpathway for rehabilitation support in joint replacement surgery has been withdrawn. This is because factual inaccuracies have been identified. NHS England no longer fund NICE to produce or maintain medtech innovation briefings, therefore these are no longer being reviewed.

    Medtech innovation briefing
    Published
    21 March 2023

  3. Spesolimab for preventing generalised pustular psoriasis flares [ID6216]

    In development [GID-TA11189] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Amyotrophic lateral sclerosis - SAR443820 [ID6386]

    In development [GID-TA11476] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care (DG30)

    This guidance has been updated and replaced by NICE's diagnostics guidance 56.

    Diagnostics guidance
    Published
    26 July 2017

  6. Medicines optimisation: key therapeutic topics – Integrated process statement (PMG13)

    February 2022: we have withdrawn our medicines optimisation: key therapeutic topics.

    We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy.

    If you have any queries, please contact nice@nice.org.uk.

  7. Process guide for adoption support resources for health technologies (PMG23)

    This process and methods guide has been withdrawn.

  8. Developing NICE guidelines: how to get involved (PMG22)

    October 2018: This process guide has been updated. The updated version can be found in the tools and resources for developing NICE guidelines: the manual.

  9. Process manual for the endorsement of guidance and quality standard support resources (PMG29)

    The endorsement programme is now closed and no new applications are being accepted. Information about existing endorsed resources, are available on the endorsement webpage. Please email endorsement@nice.org.uk if you have any queries.

  10. Into practice guide (PMG30)

    This guide has been updated and replaced by practical steps to improving the quality of care and services using NICE guidance.

  11. Key therapeutic topics – Medicines management options for local implementation: Interim process statement (PMG7)

    February 2022: we have withdrawn our medicines optimisation: key therapeutic topics.

    We have taken this decision after reviewing the wide range of services we currently provide, so we can focus on delivering the priorities outlined in our 5-year strategy.

    If you have any queries, please contact nice@nice.org.uk.

  12. SeHCAT (tauroselcholic [75 selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (DG7)

    This guidance has been updated and replaced by NICE diagnostics guidance 44.  

    Diagnostics guidance
    Published
    28 November 2012

  13. Hypersalivation: oral glycopyrronium bromide (ESUOM15)

    This evidence summary has been withdrawn because licensed products are now available and the off-label indication has been replaced by NICE guideline NG71.

    Evidence summary
    Published
    2 July 2013

  14. Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)

    This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.

    Evidence summary
    Published
    23 July 2013

  15. Type 1 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM62)

    This evidence summary has been updated and replaced by NICE guideline NG17.

    Evidence summary
    Published
    13 October 2015